Multi-CAR T Cells for Solid Tumor Heterogeneity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy methods, such as CAR T-cell therapy, face challenges in effectively targeting and overcoming tumor heterogeneity in solid tumors, where cancer cells exhibit molecular variations and express different antigens or checkpoint inhibitors, limiting their efficacy.
Innovation Solution
The method involves administering lipid particles encoding specific antigens and IL-12 to antigen-presenting cells, which enhances the expansion of both CAR T cells and bystander T cells, overcoming tumor heterogeneity by stimulating a broader immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T-cell therapy is used to target solid tumors, then anti-tumor activity is improved, but efficacy is limited due to tumor heterogeneity where cancer cells express different antigens or checkpoint inhibitors
Solution Approach 1:
The patent segments the T-cell population into multiple subsets with different CAR specificities (e.g., CD19-CAR, BCMA-CAR, GD2-CAR) to target different antigens expressed by heterogeneous tumor cells. This segmentation allows the therapy to address the diversity of tumor antigens rather than relying on a single CAR specificity, thereby overcoming tumor heterogeneity while maintaining anti-tumor activity.
Solution Approach 2:
The patent creates a universal T-cell product that can target multiple tumor antigens through co-expression of different CARs in the same T-cell population. This multi-functional approach enables the therapy to adapt to various tumor types and antigen expressions, making it versatile against heterogeneous solid tumors while preserving reliable anti-tumor efficacy.
2Ease of manufacture
If a single antigen target is used for CAR T-cell therapy, then manufacturing is simplified, but the therapy cannot overcome tumor heterogeneity effectively
Solution Approach 1:
The patent merges multiple CAR expression cassettes into a single T-cell product through simultaneous transduction or co-transduction processes. This combining approach maintains manufacturing simplicity by using standardized transduction protocols while achieving multi-antigen targeting capability, thus resolving the contradiction between ease of manufacture and adaptability to tumor heterogeneity.
Solution Approach 2:
The patent performs preliminary engineering of T-cells to co-express multiple CARs before infusion, using pre-designed lentiviral or retroviral vectors containing multiple CAR cassettes. This preliminary multi-CAR equipping allows the cells to be manufactured once with enhanced capabilities, avoiding the need for separate manufacturing processes for each CAR type, thereby maintaining ease of manufacture while achieving broad antigen targeting.
Data Source
AI summary
The present disclosure relates to compositions and methods for enhancing T cell response in vivo. For example, a method of enhancing T cell response in a subject or treating a subject having cancer, the method comprising: administering an effective amount of a composition comprising modified cells to the subject having a form of cancer associated with or expressing an antigen, for example, a solid tumor antigen; and administering (1) a nucleic acid encoding the antigen, (2) additional modified cells comprising the nucleic acid or the antigen, or (3) microorganisms, for example cold viruses, comprising the nucleic acid or the antigen. In embodiments, the modified cells comprise mixed cells targeting a solid tumor antigen and a white blood cell (WBC) antigen. In embodiments, the modified cells comprise a dominant negative form of an immune checkpoint molecule (e.g., PD-1). In embodiments, the modified cells comprise an exogenous polynucleotide encoding a therapeutic agent, such as IL-12 and IFNγ.